<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDROMET- hydrocodone bitartrate and homatropine methylbromide syrup </strong><br>Actavis Mid Atlantic LLC<br></p></div>
<h1><span class="Bold">HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE SYRUP </span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0545cf75-891f-4a90-ba0c-93b12aae1be3"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">CII</span></p>
<p>FORM NO. 1030<br>Rev. 8/14<br>VC4408</p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_6e841913-2f80-4a42-b497-61c25a416dba"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">This product contains hydrocodone (dihydrocodeinone) bitartrate, USP, a semisynthetic centrally acting narcotic antitussive. Homatropine methylbromide, USP is included in a subtherapeutic amount to discourage deliberate overdosage. Each 5 mL (one teaspoonful) contains:</p>
<p>Hydrocodone Bitartrate, USP ........................ 5 mg</p>
<p>Homatropine Methylbromide, USP ............... 1<span class="Bold">.</span>5 mg</p>
<p>The hydrocodone component is 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5), a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine, has a molecular weight of 494<span class="Bold">.</span>490, and may be represented by the following structural formula:</p>
<div class="Figure">
<img alt="0482c2a1-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a324c912-a3ef-4296-b9a8-b0fec687eb06&amp;name=hydromet-syrup-1.jpg"><p class="MultiMediaCaption">Hydrocodone Bitartrate, USP</p>
</div>
<p>Homatropine methylbromide, USP is a 3α-hydroxy-8-methyl-1αH, 5αH-tropanium bromide mandelate; a white crystal or fine white crystalline powder, with a molecular weight of 370<span class="Bold">.</span>28.</p>
<div class="Figure">
<img alt="0482c2a1-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a324c912-a3ef-4296-b9a8-b0fec687eb06&amp;name=hydromet-syrup-2.jpg"><p class="MultiMediaCaption">Homatropine Methylbromide, USP</p>
</div>
<p><span class="Bold">Inactive Ingredients: </span>artificial cherry flavor, anhydrous citric acid, D&amp;C Red #33, FD&amp;C Blue #1, FD&amp;C Red #40, methylparaben, propylene glycol, purified water, saccharin sodium, sodium benzoate, sodium citrate dihydrate, sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_85eaa868-bbd4-492e-8fd1-f84ae0791962"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center. In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23<span class="Bold">.</span>6 ± 5<span class="Bold">.</span>2 ng/mL. Maximum serum levels were achieved at 1<span class="Bold">.</span>3 ± 0<span class="Bold">.</span>3 hours and the half-life was determined to be 3<span class="Bold">.</span>8 ± 0<span class="Bold">.</span>3 hours. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-keto reduction to the corresponding 6-α- and 6-ß-hydroxymetabolites.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_c8aba673-b78d-4369-9407-c771cf7f8893"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">For the symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_5107e1a8-3679-4f4c-a467-6b57f2b19952"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Should not be administered to patients who are hypersensitive to hydrocodone or homatropine methylbromide.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_82d44922-a0d8-4d17-8dc8-43a8dab85187"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First">May be habit forming. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and, therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance may develop upon repeated administration of hydrocodone bitartrate and homatropine methylbromide, and it should be prescribed and administered with the same degree of caution appropriate to the use of other narcotic drugs (see <a href="#LINK_7b59c05f-670f-4083-8034-d4362eb65eaf">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>: </span>Hydrocodone produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by directly acting on brain stem respiratory centers. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>: </span>The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> properties of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.</p>
<p><span class="Bold">Acute Abdominal Conditions: </span>The administration of hydrocodone or other narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p><span class="Bold">Pediatric Use: </span>In young pediatric patients, as well as adults, the respiratory center is sensitive to the depressant action of narcotic <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> suppressants in a dose-dependent manner. Benefit to risk ratio should be carefully considered especially in pediatric patients with respiratory embarrassment (e.g., <span class="product-label-link" type="condition" conceptid="260134" conceptname="Croup">croup</span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_ecb9f274-f4c4-430c-99d3-df8234a75d76"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_e1375efa-086e-43eb-8790-79848e8de2c1"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">General
</span></h2>
<p class="First">Before prescribing medication to suppress or modify <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, it is important to ascertain that the underlying cause of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> is identified, that modification of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> does not increase the risk of clinical or physiological complications, and that appropriate therapy for the primary disease is provided.</p>
<p><span class="Bold">Special Risk Patients: </span>Hydrocodone bitartrate and homatropine methylbromide should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison’s disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_8091477d-a5cf-46ac-a01b-2060c11fef29"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Information for Patients
</span></h2>
<p class="First">Hydrocodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this product should be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_42f46e1f-7789-44be-8776-c6dad9827a69"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Drug Interactions
</span></h2>
<p class="First">Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and homatropine methylbromide may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When combined therapy is contemplated, the dose of one or both agents should be reduced. The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_eb6916a6-3776-45c7-a091-bfaf7349c20f"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></h2>
<p class="First">Studies of hydrocodone bitartrate and homatropine methylbromide in animals to evaluate the carcinogenic and mutagenic potential and the effect on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_2a14535d-219c-441d-8c47-b5c98300a5da"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">Pregnancy
</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_8aca2a8a-c598-40e2-8c7e-7406b6346d4e"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects
</span></h3>
<p class="First"><span class="Italics">Pregnancy Category C</span>. Animal reproduction studies have not been conducted with hydrocodone bitartrate and homatropine methylbromide. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hydrocodone bitartrate and homatropine methylbromide should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_b4ca8712-4616-4dad-8949-88ed39e034f3"></a><a name="section-7.5.2"></a><p></p>
<h3><span class="Bold">Nonteratogenic Effects
</span></h3>
<p class="First">Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_c1c8997b-2003-4479-b6c9-e7d6a92e6520"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">Labor and Delivery
</span></h2>
<p class="First">As with all narcotics, administration of hydrocodone bitartrate and homatropine methylbromide to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_11e2ea73-917d-47e6-b4c5-f9ac28fad6e6"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">Nursing Mothers
</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone bitartrate and homatropine methylbromide, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_49c81bb6-6932-48df-9233-972f128b6bb9"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">Pediatric Use
</span></h2>
<p class="First">Safety and effectiveness of hydrocodone bitartrate and homatropine methylbromide in pediatric patients under six have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7b9f84b1-cb3c-4264-8604-99c9b495330c"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First"><span class="Bold">Central Nervous System: </span>Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>.</p>
<p><span class="Bold">Gastrointestinal System: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur; they are more frequent in ambulatory than in recumbent patients. Prolonged administration of hydrocodone bitartrate and homatropine methylbromide may produce <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold">Genitourinary System: </span>Ureteral spasm, spasm of vesical sphincters and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have been reported with opiates.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>: </span>Hydrocodone may produce dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on brain stem respiratory centers (see <a href="#LINK_b503ecc3-e04e-49c4-a27a-0ea3021e4c0b">OVERDOSAGE</a>).</p>
<p><span class="Bold">Dermatological: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_7b59c05f-670f-4083-8034-d4362eb65eaf"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</span></h1>
<p class="First">Hydrocodone bitartrate and homatropine methylbromide syrup is a Schedule II controlled substance. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance may develop upon repeated administration of narcotics; therefore, hydrocodone bitartrate and homatropine methylbromide should be prescribed and administered with caution. However, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is unlikely to develop when hydrocodone bitartrate and homatropine methylbromide is used for a short time for the treatment of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral narcotic use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of narcotic therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_b503ecc3-e04e-49c4-a27a-0ea3021e4c0b"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First"><span class="Bold">Signs and Symptoms: </span>Serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. The ingestion of very large amounts of this product may, in addition, result in acute homatropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p><span class="Bold">Treatment: </span>Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated, including treatment for anticholinergic drug <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Gastric emptying may be useful in removing unabsorbed drug.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e3a360c0-e957-48d7-8b53-a1691863b51d"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First"><span class="Bold">Adults: </span>One (1) teaspoonful (5 mL) every four to six hours as needed; do not exceed six (6) teaspoonfuls in 24 hours.</p>
<p><span class="Bold">Children 6 to 12 years of age: </span>One-half (½) teaspoonful (2<span class="Bold">.</span>5 mL) every four to six hours as needed; do not exceed three (3) teaspoonfuls in 24 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_fa44305c-1173-41fc-be15-0ac5d2074e54"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED </span></h1>
<p class="First">This preparation is a red colored, cherry flavored syrup containing 5 mg hydrocodone bitartrate, USP and 1<span class="Bold">.</span>5 mg homatropine methylbromide, USP per 5 mL, and is available in one pint (473 mL) bottles.</p>
<p>Store at controlled room temperature 15° to 30°C (59° to 86°F).</p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
<p>Oral prescription where permitted by State Law.</p>
<p><span class="Bold">Manufactured by:<br></span>G&amp;W NC Laboratories, LLC<br>1877 Kawai Road<br>Lincolnton, NC 28092 USA</p>
<p><span class="Bold">Distributed by:<br></span>Actavis Pharma, Inc.<br>Parsippany, NJ 07054 USA</p>
<p>FORM NO. 1030<br>Rev. 8/14<br>VC4408</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_bb011f18-e58d-441d-8bdc-5070508b0e0f"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<div class="Figure"><img alt="0482c2a1-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a324c912-a3ef-4296-b9a8-b0fec687eb06&amp;name=hydromet-syrup-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROMET 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate and homatropine methylbromide syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0472-1030</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCODONE BITARTRATE</strong> (HYDROCODONE) </td>
<td class="formItem">HYDROCODONE BITARTRATE</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HOMATROPINE METHYLBROMIDE</strong> (METHYLHOMATROPINE) </td>
<td class="formItem">HOMATROPINE METHYLBROMIDE</td>
<td class="formItem">1.5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CHERRY</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0472-1030-16</td>
<td class="formItem">473 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088017</td>
<td class="formItem">09/30/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Mid Atlantic LLC
							(809515898)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">G&amp;W NC Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">079419931</td>
<td class="formItem">ANALYSIS(0472-1030), LABEL(0472-1030), MANUFACTURE(0472-1030), PACK(0472-1030)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6ea55b8d-8e84-464a-bb4c-8c3b49f40e26</div>
<div>Set id: a324c912-a3ef-4296-b9a8-b0fec687eb06</div>
<div>Version: 7</div>
<div>Effective Time: 20141003</div>
</div>
</div> <div class="DistributorName">Actavis Mid Atlantic LLC</div></p>
</body></html>
